Dig into the minds of members and you'll find that they don't always make logical choices. Behavioral economics can shed light on their thought process
Only 20% of PDPs will offer gap coverage, and even then, most are limited to generics. House and Senate bills aim to help out.
Healthcare is funded by taxes and subsidies, but privately insured people are encouraged to buy upgrades
Physicians must evaluate the use of antidepressant medications based on new guidelines from two gynecological organizations
Recognize the interrelated health risks among four prevalent conditions to better manage big-picture treatment goals
Outcomes-based contracting enables risk sharing between plans and manufacturers while also allowing better patient adherence to regimens
The healthcare industry has yet to use evidence-based medicine (EBM) to its fullest potential, despite studies suggesting the need for it. Wide variation in medical practice and resulting clinical outcomes is indicative of the not-yet completed journey toward implementing evidence-based medicine.
Biogenerics will not be taking the U.S. marketplace by storm any time soon. Approval of biogenerics is creating a rift between innovators and generic manufacturers and is putting data exclusivity and interchangeability to the test
What works for retail pharmacy patients should work for mail-order recipients, namely, personalized drug counseling. When consumers pick up their prescriptions at a local pharmacy, they have access to pharmacists who can advise them on how and when to take medications, warn them of potential side effects and discuss generic alternatives.
For payers struggling with unmanageable cost increases in the business of delivering care, however, price cannot be overlooked. Insurers don't necessarily deny coverage of a treatment just because it's expensive, but they would be remiss if they didn't take cost into consideration, as well as safety and effectiveness.